pharmacology

pharmacology

pharmacology

Reactions: method developed to produce protein-based drugs that can be administered orally

For the treatment of many diseases it is necessary to use large molecules that do not resist the digestion process and must be injected. Now, a group of scientists at the Institute of Chemical Sciences and Engineering in Lausanne (Switzerland) has developed a method for synthesizing a type of protein called cyclic peptides, capable of binding to varied and complex targets, and they have done so in a way that makes them capable of being administered orally. According to the press release accompanying the publication, this opens "a new era in drug development".

0

What we know about biosimilar medicines

Biosimilars work in a similar way to biologics - which are made from living cells and are very complex and expensive - such as insulin, growth hormone, vaccines and monoclonal cancer antibodies. We explain what savings biosimilars bring to the healthcare system and what the process is to ensure that their quality, efficacy and safety are equivalent to those of the reference medicine.

0

Reactions to the approval of lecanemab for the treatment of Alzheimer's patients in the US

The drug lecanemab (Leqembi™) has received full approval as a treatment for early Alzheimer's disease by the US Food and Drug Administration (FDA), after confirming its clinical benefit in a trial involving 1,795 patients. The FDA highlights the warning that in rare cases it can cause serious and potentially life-threatening side effects.

0

Reaction: study shows Alzheimer's drug lecanemab helps neutralise the effects of small toxic amyloid aggregates

Research led by scientists at Harvard Medical School (USA) has isolated small aggregates of amyloid from the brains of post-mortem Alzheimer's patients. The achievement has made it possible to study the structure of these "clumps", which exist outside plaques and are considered highly toxic, and to test their effect on synapses. In addition, the authors have shown that the drug lecanemab, recently approved by the FDA, is able to bind to them and help neutralise their action. The results are published in the journal Neuron.

0

Reactions: Alzheimer's drug donanemab shows positive results in phase III trial, says drugmaker Eli Lilly

A press release from Eli Lilly claims that its antibody treatment, donanemab, significantly slowed cognitive and functional decline in a phase 3 study of early-stage Alzheimer's disease. The results have not yet been published in a scientific journal.

0

Reaction: Study finds "major deficiencies" in cancer drug information provided to patients and doctors

Research published in The BMJ has compared the information on cancer drugs available to regulatory authorities with that officially received by doctors and patients. According to the authors, important information is often omitted. In particular, "none of the package inserts communicated information about the benefits of the drug that patients could expect based on the results of the studies". In addition, doubts raised by European evaluators about the reliability of the evidence "were rarely communicated to physicians, patients or the public," they say.

0

Reaction: meta-analysis finds lack of scientific evidence on efficacy and safety of painkillers for low back pain

A meta-analysis analysing 98 published clinical trials highlights the lack of scientific evidence on the efficacy and safety of commonly used analgesic drugs for acute low back pain (such as anti-inflammatory drugs, paracetamol and opioids, among others). The study, published in The BMJ, includes data from more than 15,000 people. It concludes that there is "considerable uncertainty" about the efficacy of these drugs in reducing the severity of non-specific acute low back pain and calls on doctors and patients to use them with caution.

0

Reaction: taking calcium supplements to prevent fractures is not justified in the general population

Available studies show no difference in the risk of different types of fracture between those who take calcium supplements and those who do not, according to a report by the Iberoamerican Cochrane Centre via Nutrimedia. According to the report, these supplements have side-effects and do not provide benefits in the general population and are therefore only recommended for people living in residential homes or other institutions.   

0